EA201790290A1 - Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения - Google Patents

Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения

Info

Publication number
EA201790290A1
EA201790290A1 EA201790290A EA201790290A EA201790290A1 EA 201790290 A1 EA201790290 A1 EA 201790290A1 EA 201790290 A EA201790290 A EA 201790290A EA 201790290 A EA201790290 A EA 201790290A EA 201790290 A1 EA201790290 A1 EA 201790290A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
fluoro
triazol
carboxylate
oxo
Prior art date
Application number
EA201790290A
Other languages
English (en)
Inventor
Марк Хендерсон
Колм Кэмпбелл
Карстен Ягуш
Кристиан Клаус Герц
Нико Бауэр
Тьерри Бонно
Оливье Ламберт
Original Assignee
Медивэйшн Текнолоджиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медивэйшн Текнолоджиз, Инк. filed Critical Медивэйшн Текнолоджиз, Инк.
Publication of EA201790290A1 publication Critical patent/EA201790290A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Abstract

В настоящем изобретении описаны коформерные соли (2S,3S)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1Н-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата, необязательно в виде сольвата, а также необязательно в виде гидрата, включая кристаллические формы, и способы получения (2S,3S)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1Н-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата, необязательно в виде коформерных солей.
EA201790290A 2014-07-31 2015-07-30 Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения EA201790290A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031521P 2014-07-31 2014-07-31
PCT/US2015/042867 WO2016019125A1 (en) 2014-07-31 2015-07-30 Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them

Publications (1)

Publication Number Publication Date
EA201790290A1 true EA201790290A1 (ru) 2017-07-31

Family

ID=55218310

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790290A EA201790290A1 (ru) 2014-07-31 2015-07-30 Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения

Country Status (15)

Country Link
US (3) US20170217921A1 (ru)
EP (1) EP3174855B1 (ru)
JP (3) JP2017523243A (ru)
KR (1) KR20170038850A (ru)
CN (1) CN107155326B (ru)
AU (1) AU2015296289B2 (ru)
BR (1) BR112017001977A2 (ru)
CA (1) CA2956714A1 (ru)
EA (1) EA201790290A1 (ru)
ES (1) ES2947501T3 (ru)
IL (1) IL250365B (ru)
MX (1) MX2017001416A (ru)
SG (1) SG11201700734RA (ru)
TW (1) TWI693214B (ru)
WO (1) WO2016019125A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625817T3 (es) 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
JP5883397B2 (ja) 2010-02-03 2016-03-15 ビオマリン プハルマセウトイカル インコーポレイテッド Ｐｔｅｎ欠損に関連した疾患の治療におけるポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）のジヒドロピリドフタラジノン阻害剤の使用
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
TWI557123B (zh) 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
RU2020113246A (ru) 2017-10-13 2021-11-15 Мерк Патент Гмбх Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
EP3876940A1 (en) 2018-11-05 2021-09-15 Pfizer Inc. Combinations for treating cancer
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
AU2021379314A1 (en) 2020-11-13 2023-06-15 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
US20240052423A1 (en) 2020-12-07 2024-02-15 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
JP2024510666A (ja) 2021-03-24 2024-03-08 ファイザー・インク Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415504A (en) * 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS5852253A (ja) * 1981-09-21 1983-03-28 Tanabe Seiyaku Co Ltd Ρ−ヒドロキシフエニルグリシン・α−フエニルエタンスルホン酸塩及びその光学分割法
JPS63192753A (ja) * 1987-02-05 1988-08-10 Otsuka Pharmaceut Co Ltd テトラヒドロキノリン誘導体の光学分割法
JPH08322591A (ja) * 1995-06-02 1996-12-10 Sumitomo Pharmaceut Co Ltd 光学分割により光学的に純粋な１，２，３，４−テトラヒドロキノリン−２−酢酸エステル類を得る方法
WO2009024190A1 (en) * 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5 )
CN101298452A (zh) * 2008-06-30 2008-11-05 南京华威医药科技开发有限公司 S-(-)-那氟沙星及其水溶性盐的制备方法和用途
ES2625817T3 (es) * 2008-08-06 2017-07-20 Medivation Technologies, Inc. Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP)
BRPI0914556A2 (pt) * 2008-08-12 2015-08-04 Boehringer Ingelheim Int Processo para a preparação de compostos de piperazina substituídos por cicloalquila
KR101826652B1 (ko) 2010-02-08 2018-02-07 메디베이션 테크놀로지즈, 인크. 디히드로피리도프탈라지논 유도체의 합성 방법
TWI557123B (zh) * 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma

Also Published As

Publication number Publication date
US20210094930A1 (en) 2021-04-01
NZ728634A (en) 2021-09-24
EP3174855B1 (en) 2023-05-10
CA2956714A1 (en) 2016-02-04
EP3174855A4 (en) 2018-03-21
KR20170038850A (ko) 2017-04-07
SG11201700734RA (en) 2017-02-27
WO2016019125A1 (en) 2016-02-04
BR112017001977A2 (pt) 2017-11-21
EP3174855A1 (en) 2017-06-07
ES2947501T3 (es) 2023-08-10
JP2017523243A (ja) 2017-08-17
CN107155326A (zh) 2017-09-12
AU2015296289A1 (en) 2017-03-02
TW201617319A (zh) 2016-05-16
US20170217921A1 (en) 2017-08-03
US20190106401A1 (en) 2019-04-11
IL250365A0 (en) 2017-03-30
MX2017001416A (es) 2017-05-19
TWI693214B (zh) 2020-05-11
IL250365B (en) 2021-02-28
JP2020125303A (ja) 2020-08-20
CN107155326B (zh) 2021-03-05
AU2015296289B2 (en) 2020-02-27
JP2022116288A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
EA201790290A1 (ru) Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
EA201890493A1 (ru) РЕПРЕССОРЫ Htt И ИХ ПРИМЕНЕНИЕ
MX2022016566A (es) Composiciones que comprenden una caseina y metodos para producir las mismas.
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201791304A1 (ru) Производные изохинолина для лечения вич
MX362259B (es) Modificador del sabor dulce que tiene la formula estructural (i): 4-amino-2,2-dióxido-1h-benzo-(1,2,6)tiadiazin; composiciones que lo comprenden y un método para incrementar el sabor dulce.
EA201590330A1 (ru) Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения
EA201690764A1 (ru) Ингибитор грелин-o-ацилтрансферазы
EA201891342A1 (ru) Изоиндольные соединения
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201792014A1 (ru) Ацетатная соль бупренорфина и способы получения бупренорфина
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201692288A1 (ru) Способ получения фосфорсодержащих циангидринов
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
EP3530216C0 (en) SURGICAL BUR
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MX2015010854A (es) Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
PH12017500492A1 (en) Crystalline bace inhibitors